Form 4 for TVRD Tvardi Therapeutics, Inc.
Accepted 2021-11-03 00:00:00 ET · period of report 2021-10-29 · accession 0001209191-21-062593 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-11-03 | 2021-10-29 | TVRD | Posner Christopher | Dir, Senior Advisor | A - Grant | $0.00 | +147.9K | 22.0K | New | $0 |
| D | 2021-11-03 | 2021-10-29 | TVRD | Posner Christopher | Dir, Senior Advisor | A - Grant | $0.00 | +566.0K | 566.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-10-29 | A | A | 142,000 | $0.00 | 164,037 | D | — | — | (F2) Represents the number of shares underlying RSUs granted to the Reporting Person pursuant to the Employment Agreement. Each RSU represents the contingent right to receive one share of common stock of the Issuer. 25% of the RSUs will vest on October 29, 2022 and the remainder will vest over the following 12 equal quarterly installments, in each case, subject to the Reporting Person's continued service to the Issuer as of each such date. |
| 2 | Common | Common Stock | 2021-10-29 | A | A | 5,941 | $0.00 | 22,037 | D | — | — | (F1) Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to an Employment Agreement, dated October 29, 2021, between the Reporting Person and the Issuer, whereby the Reporting Person is employed as a Senior Advisor to the Issuer effective October 29, 2021 and as President and Chief Executive Officer of the Issuer effective November 9, 2021 (the "Employment Agreement"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs will vest in full on March 31, 2022, subject to the Reporting Person's continued service to the Issuer on such date. |
| 3 | Derivative | Stock Option (Right to Buy) | 2021-10-29 | A | A | 566,000 | $0.00 | 566,000 | D | $16.83 · — to 2031-10-29 | 566,000 Common Stock | (F3) 25% of the shares will vest and become exercisable on October 29, 2022 and the remainder will vest over the following 12 equal quarterly installments, in each case, subject to the Reporting Person's continued service to the Issuer as of each such date. These options were granted to the Reporting Person pursuant to the Employment Agreement. |